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Abstract
Glycogen, a branched polymer of glucose, functions as an energy reserve in many living organ-
isms. Abnormalities in glycogen metabolism, usually excessive accumulation, can be caused gen-
etically, most often through mutation of the enzymes directly involved in synthesis and
degradation of the polymer leading to a variety of glycogen storage diseases (GSDs). Microscopic
visualization of glycogen deposits in cells and tissues is important for the study of normal glyco-
gen metabolism as well as diagnosis of GSDs. Here, we describe a method for the detection of
glycogen using a renewable, recombinant protein which contains the carbohydrate-binding mod-
ule (CBM) from starch-binding domain containing protein 1 (Stbd1). We generated a fusion protein
containing glutathione S-transferase, a cMyc eptitope and the Stbd1CBM (GYSC) for use as a
glycogen-binding probe, which can be detected with secondary antibodies against glutathione S-
transferase or cMyc. By enzyme-linked immunosorbent assay, we demonstrate that GYSC binds
glycogen and two other polymers of glucose, amylopectin and amylose. Immunofluorescence
staining of cultured cells indicate a GYSC-specific signal that is co-localized with signals obtained
with anti-glycogen or anti-glycogen synthase antibodies. GYSC-positive staining inside of lyso-
somes is observed in individual muscle fibers isolated from mice deficient in lysosomal enzyme
acid alpha-glucosidase, a well-characterized model of GSD II (Pompe disease). Co-localized GYSC
and glycogen signals are also found in muscle fibers isolated from mice deficient in malin, a mod-
el for Lafora disease. These data indicate that GYSC is a novel probe that can be used to study
glycogen metabolism under normal and pathological conditions.
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Introduction
Glycogen is a branched polymer of glucose and is the primary
carbohydrate storage form in animals (Agius 2008; Roach et al.
2012). Glycogen synthesis and degradation are tightly controlled by
complex regulatory mechanisms (Agius 2008; Roach et al. 2012;
Adeva-Andany et al. 2016). Disturbances in this regulation or in the
metabolic enzymes themselves can result in aberrant glycogen stores,
resulting in a glycogenosis or glycogen storage disease (GSD) (Chen
and Burchell 1995; DiMauro and Lamperti 2001; DiMauro and
Spiegel 2011; Oldfors and DiMauro 2013). These are monogenic,
congenital disorders in which a genetic defect results in abnormal
amounts and/or structure of glycogen. The first examples involved
mutations linked directly to glycogen metabolizing enzymes, such as
GSD II (Pompe disease) in which the lysosomal α-glucosidase is
defective (Reuser et al. 1995; Hirschhorn and Reuser 2000; Raben
et al. 2002). Histochemical staining of glycogen is therefore import-
ant diagnostically, the most commonly used method being periodic
acid Schiff (PAS) staining that visualizes molecules with a high per-
centage of carbohydrate content (McManus 1946; Hotchkiss 1948).
One disadvantage of PAS staining for the detection of glycogen in
tissues is lack of specificity. Besides glycogen, PAS staining detects
other carbohydrate containing molecules including glycoproteins,
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glycolipids and mucins (McManus 1946; Hashimoto et al. 1965;
Dahr et al. 1976). Indeed, it is used in diagnosis of conditions such
as Paget’s disease of the breast (Crignis et al. 2013), adenocarcin-
oma (Warnock et al. 1988), glomerular diseases in the kidney
(Nakatani et al. 2004) and others. Another disadvantage of PAS
staining is its general incompatibility with immunofluorescence
staining techniques, precluding analysis of the co-localizaton of
glycogen with protein molecules, an approach that could be useful
for elucidation of molecular mechanisms underlying various GSDs.
An antibody that recognizes glycogen (IV58B6) has been quite
widely used in studies of cells and tissues. Baba (1993) used man-
dibular condylar cartilage as an antigen to produce monoclonal anti-
bodies in mouse that were subsequently found to recognize glycogen
although cross-reactivity with other molecules cannot be rigorously
excluded. We sought to generate a new renewable probe to specific-
ally detect glycogen in cultured cells or tissues. The probe contains
the carbohydrate-binding module (CBM) from human starch-binding
domain containing protein 1 (Stbd1) fused to GST and c-myc tags.
Human Stbd1 is a 39 kDa protein that consists of a highly conserved
N-terminal hydrophobic sequence that targets the protein to mem-
branes, a disordered central region and a C-terminal CBM20, that
has been shown to bind to glycogen (Jiang et al. 2010). We validate
that the resulting probe can bind to glycogen in vitro and that it can
be used for immunofluorescent detection of glycogen in mammalian
cells and in individual muscle fibers from mouse models of Lafora and
Pompe diseases. Furthermore, this probe is compatible for protein
co-localization studies.
Results
Design, expression and purification of a glycogen-
binding probe
Previous studies had demonstrated that Stbd1 binds to glycogen
in vitro and co-localized with glycogen in mammalian cells (Jiang
et al. 2010). To generate a probe capable of detecting glycogen, we
designed a bacterial expression plasmid that would encode a fusion
protein containing glutathione S-transferase (GST), a cMyc-tag and a
carbohydrate-binding module corresponding to residues 261–358 of
human Stbd1 (Figure 1 A). The resulting protein, named GYSC, was
expressed in Escherichia coli strain BL21, purified by absorption on
glutathione-agarose beads, eluted with glutathione and analyzed by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). Purified fractions contained a predominant band with Mr ~
39kDa (Figure 1B).
Carbohydrate-binding specificities of GYSC
and anti-glycogen antibody
In order to characterize the carbohydrate-specificity of GYSC, we
used glycogen and two other glycogen-like polymers, amylopectin
and amylose, which differ from glycogen in their degree of branch-
ing. Mammalian glycogen is branched on average at 1 in ~13 glu-
cose residues, amylopectin 1 in 20–25 and amylose is scarcely
branched at all (Roach et al. 2012; Roach and Zeeman 2016).
Binding analysis was performed by enzyme-linked immunosorbent
assay (ELISA). GYSC bound to all three polymers of glucose with
slightly higher affinity to amylopectin and lower affinity to amylose,
as compared to glycogen (Figure 2 A). Half maximal effective con-
centrations (EC50) of glycogen, amylopectin and amylose for GYSC
binding were 0.18, 0.07 and 0.57 μg/mL, respectively. We also ana-
lyzed binding of the Baba antibody (Baba 1993) to the same
polysaccharides. As expected, this antibody bound glycogen (EC50 =
0.92 μg/mL) but it did not recognize amylopectin or amylose
(Figure 2B), consistent with a previous report that the epitopes
recognized by Baba antibody correspond to densely branched
regions of glycogen (Nakamura-Tsuruta et al. 2012). Therefore,
GYSC is less sensitive to the branching pattern of polysaccharides
than the Baba antibody. Data on the glucan binding characteristics
of the Stbd1 CBM20 domain are sparse but the results are consistent
with the known substrate-binding specificity of CBM20 domains
from other proteins. Previous studies demonstrated that CBM20 has
optimal affinity towards linear maltooligosaccharides of approxi-
mately DP7 composed of solely α-(1–4) linkages and it does not
bind oligosaccharides smaller than maltopentaose (Sorimachi et al.
1997; Giardina et al. 2001; Tanackovic et al. 2016)
Detection of glycogen by GYSC in mammalian cells
To test whether GYSC can detect glycogen in mammalian cells, we
first utilized Rat-1 fibroblasts that stably overexpress glycogen syn-
thase (WT-4 line) (Skurat et al. 2000) and have a 5-fold increase in
glycogen accumulation over control cells (not shown). In this cell
model, large glycogen deposits were localized predominantly in a
perinuclear area as detected by immunofluorescence microscopy
using the anti-glycogen antibody (Figure 3B). With GYSC as a
glycogen probe (Figure 3 A), detection of GYSC with anti-GST anti-
bodies for the most part overlapped the staining obtained with the
anti-glycogen antibody (Figure 3 C). Glycogen synthase is closely
associated with glycogen in cells (Prats et al. 2009) and so we also
Fig. 1. Scheme for experimental procedures with GYSC and analysis of purified
GYSC by SDS-PAGE. In (A), a fusion protein GYSC containing the CBM20
domain from human Stbd1 with attached two epitope tags, cMyc (myc) and
GST is shown. The CBM20 domain serves for binding of GYSC to glycogen,
whereas GST-tag is used for detection of glycogen-bound GYSC by either ELISA
or immunofluorescent microscopy. In both methods, the GYSC–glycogen com-
plex is incubated first with rabbit anti-GST antibody and then with anti-rabbit
secondary antibody conjugated with HRP (ELISA) or fluorophore (Texas Red is
shown as an example). In (B), Coomassie blue stained SDS-PAGE gel of purified
GYSC is shown. Numbers on the left indicate migration of molecular mass mar-
kers (in kDa). GYSC, a fusion protein composed of glutathione S-transferase, a
cMyc eptitope and the Stbd1CBM; SDS-PAGE, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis; CBM, carbohydrate-binding module; GST,
glutathione S-transferase; ELISA, enzyme-linked immunosorbent assay; HRP,
horseradish peroxidase.This figure is available in black and white in print and in
color at Glycobiology online.
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compared the localization of GYSC and glycogen synthase
(Figure 3D–F), in this experiment visualizing GYSC with anti-c-myc
antibodies. The results indicate a strong co-localization of GYSC and
glycogen synthase (Figure 3 F). In addition, there was a similar pattern
of GYSC staining whether it was detected by α-GST or α-cMyc anti-
bodies, providing further validation of the GYSC localization.
In a second series of experiments, we tested whether GYSC could
detect endogenous glycogen in wild type Rat-1 fibroblasts and moni-
tor its response to changes in nutritional status. In cells grown under
standard conditions with 25mM glucose, immunofluorescence
microscopy revealed GYSC- and anti-glycogen antibody-positive
staining in small punctate structures scattered throughout the cyto-
plasm (not shown but similar to the pattern in Figure 4D–F).
Starvation of cells in medium lacking glucose led to disappearance of
this staining by either GYSC or anti-glycogen antibody (Figure 4A–C).
Refeeding of starved cells with medium containing 25mM glucose
for 6 h caused re-appearance of the punctate staining. Signals from
GYSC and anti-glycogen antibody demonstrated near complete
co-localization (Figure 4 F). As further proof that the observed
immunofluorescent labeling is due to glycogen, we treated re-fed
fixed cells with glycogen-degrading enzymes prior to incubation
with GYSC or anti-glycogen antibody. Treatment with either dia-
stase (Figure 4 G) or amyloglucosidase (Figure 4H) completely
eliminated the labeling, confirming that glycogen is necessary for
GYSC or the Baba antibody to generate a fluorescence signal.
GYSC- and anti-glycogen antibody-staining correlated with enzym-
atic measurements of glycogen in Rat-1 fibroblasts. Indeed, glucose
starvation caused almost 20-fold decrease in glycogen level and
refeeding for 6 h almost completely restored it (Figure 4I). The punc-
tate pattern of glycogen distribution was also observed in other
mammalian cells (not shown).
In a further control, we sought to confirm that the signal detected
with GYSC required the presence the Stbd1 CBM20 domain.
Therefore, with re-fed Rat-1 fibroblasts, we compared GYSC and
purified GST protein as probes for glycogen (Figure 5 A,D). GYSC
gave the expected punctate pattern (as in Figure 4D), whereas no sig-
nal was detected with GST alone (Figure 5D), indicating that the
GYSC signal is specific. The cells were also probed with α-glycogen
synthase antibodies as a mean to localize glycogen resulting in the
normal punctate distribution (Figure 5B,E). Thus, the normal glyco-
gen pattern was present even when GST failed to reveal any signal.
GYSC detection of glycogen in muscle of mouse
models of GSDs
Aberrant glycogen structure and deposition are associated with the
various GSDs. To determine whether GYSC could be used for ana-
lysis of abnormal glycogen stores, we utilized two mouse models for
GSDs, Lafora and Pompe disease. In Lafora disease, mutations of
either the Epm2a or Epm2b genes lead to the formation of insoluble
deposits of abnormal glycogen that is a major constituent of Lafora
bodies, a hallmark of the disease in humans and mice (Collins et al.
1968; Carpenter and Karpati 1981; Ganesh et al. 2002; DePaoli-
Roach et al. 2010). The glycogen is poorly branched and excessively
Fig. 2. Binding analysis of GYSC or glycogen antibody to polysaccharides. Binding of GYSC (A) or anti-glycogen antibody (B) to glycogen (diamonds), amylo-
pectin (squares) or amylose (triangles) was analyzed by ELISA as described in the “Materials amd methods” section. Error bars indicate SD for four independ-
ent experiments. This figure is available in black and white in print and in color at Glycobiology online.
Fig. 3. Co-localization of GYSC, glycogen and glycogen synthase (GS). Rat-1
fibroblasts stably expressing wild type glycogen synthase (cell line WT-4)
were immunostained with GYSC and anti-glycogen antibody (A–C) or GYSC
and anti-glycogen synthase antibody (D–F). To detect GYSC localization
either anti-GST antibody (A–C) or anti-C-myc antibody (D–F) were used. The
images were merged (C and F). Nuclei were stained with Hoechst. This figure
is available in black and white in print and in color at Glycobiology online.
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phosphorylated (Tagliabracci et al. 2007, 2008). Lafora bodies are
found in many tissues, including skeletal muscle, heart, skin and
neurons, the last likely being causative of the associated epilepsy
and neurodegeneration (Van Heycop Ten Ham 1975; Delgado-
Escueta et al. 2001). Immunofluorescence imaging of individual
muscle fibers from Epm2b–/– mice revealed multiple deposits stained
with both GYSC and anti-glycogen antibody (Figure 6). These data
indicate that GYSC stains the abnormal glycogen-like material in
Lafora bodies.
In Pompe disease, lysosomal glycogen disposal is defective due to
mutation of the lysosomal α-glucosidase (acid maltase; GAA) resulting
in massive accumulation of glycogen in the lysosomes, disrupting
autophagic trafficking and lysosome function generally (Hirschhorn
and Reuser 2000; Raben et al. 2008). Skeletal muscle and heart are
typically the organs most affected. Analysis of muscle fibers from a
mouse model of Pompe disease by confocal microscopy revealed a dif-
ferent pattern of GYSC staining (Figure 7) compared with the
Epm2b–/– fibers. GYSC-positive structures of irregular shape were
scattered throughout the depth and length of the muscle fiber.
Staining with antibody against an endosomal/lysosomal marker,
LAMP1, demonstrated markedly enlarged lysosomes, a characteristic
feature of Pompe disease. Staining using both GYSC and LAMP1
antibody indicated that GYSC-positive material is localized inside the
lysosomes (Figure 7). No GYSC-positive staining was seen inside the
lysosomes in muscle fibers isolated from wild type mice (not shown).
Discussion
Glycogen particles in muscle have average dimensions of ~25 nm
(Shearer and Graham 2004) and so visualization at a true molecular
level requires electron microscopy. However, detection of glycogen
in cells and tissues has long been achieved by histochemical meth-
ods, the most common of which is PAS staining whereby oxidation
of hydroxyls in glucose residues by periodic acid is followed by reac-
tion of the resulting aldehydes with Schiff reagent to generate a pur-
ple or magenta color (Pearse 1961). The stain detects any structure
with a high content of carbohydrate, including glycogen. PAS-
stained sections of liver cells, for example, even at relatively low
Fig. 4. Detection of endogenous glycogen in Rat-1 fibroblasts with GYSC. Rat-1 fibroblasts were starved in the medium lacking glucose for 48 h. Cells were then
left either in the no glucose medium (A–C) or incubated in the medium containing 25mM glucose for 6 h (D–H). To digest glycogen, fixed cells were treated with
diastase (G) or amyloglucosidase (H). Glycogen was visualized with GYSC or anti-glycogen antibody. GYSC was detected with anti-GST antibody. The images
were merged (C, F, G and H). Nuclei were stained with Hoechst. Glycogen content in starved, re-fed and nonstarved Rat-1 fibroblast from one representative
experiment is shown (I). This figure is available in black and white in print and in color at Glycobiology online.
Fig. 5. Co-localization of GYSC and GST with glycogen synthase (GS). Rat-1
fibroblasts were starved and refed as described in the legend to Figure 4.
Fixed cells were incubated with GYSC (A–C) and GST (D–F) followed by incu-
bation with anti-GST and anti-glycogen synthase antibody. Nuclei were
stained with Hoechst. This figure is available in black and white in print and
in color at Glycobiology online.
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magnification, readily indicate the level of glycogen stored in the
hepatocytes via the intensity of the staining (Hammad et al. 1982).
PAS staining has also been used extensively to assist in the diagnosis
of a variety of GSDs (Sato 2002; Kishnani et al. 2010; Escobar et al.
2012).
Glycogen is generally associated with the proteins involved in its
metabolism and so immunochemical detection of these proteins might
provide a surrogate to identify glycogen localization. Glycogen syn-
thase, for example, is often tightly associated with glycogen and
commercial antibodies are available. However, under some physio-
logical and pathological conditions, glycogen and glycogen synthase
are not co-localized. For example, glycogen synthase is present only
in the cytosol in several mammalian cell lines under normal condi-
tions but prolonged exposure of cells in glucose-free medium or acti-
vation of glycogen phosphorylase causes glycogen depletion and
translocation of glycogen synthase from the cytosol to the nucleus
(Cid et al. 2005). Another example of lack of co-localization of
glycogen and glycogen synthase is in Pompe disease that is caused
by deficiency of the lysosomal glycogen-degrading enzyme, acid
α-glucosidase. Lysosomal protein-degrading enzymes are unaffected
and thus glycogen accumulation in lysosomes could not be reliably
followed by glycogen synthase.
Finally, the amount of glycogen synthase in tissues does not
always correlate with the amount of glycogen. For example, starva-
tion causes dramatic reduction of glycogen in liver and adipose tis-
sue without substantial alteration in glycogen synthase expression
(Gannon and Nuttall 1997; Carmean et al. 2016). Therefore, com-
parative analysis of glycogen levels in different metabolic states can-
not be performed using anti-glycogen synthase antibodies.
Antibodies have been developed that purport to directly recog-
nize glycogen (Baba 1993; Nakamura-Tsuruta et al. 2012). These
antibodies are not commercially available and we decided to develop
a more directed and renewable probe for glycogen, GYSC, based on
the properties of the CBM domain of the protein Stbd1. We had
previously proposed that Stbd1 is involved in glycogen metabolism
and, even though its precise role remains unclear, we have shown
that Stbd1 binds to glycogen, in vitro and in cells (Jiang et al. 2010).
In the present study, we believe that we have validated the effective-
ness of GYSC as a novel probe to detect glycogen in cultured cells
and isolated mouse muscle fibers.
Part of the validation was to compare GYSC with the Baba anti-
glycogen antibody. In vitro, both recognized mammalian glycogen
as judged by ELISA. GYSC also bound to the less branched plant
polysaccharides amylopectin and amylose whereas the Baba anti-
body did not, at least under the conditions used. In fact, the inability
of the Baba antibody to bind less branched polymers of glucose has
been described in previous studies by van de Weerd et al. (2015)
who proposed that the result was explained by the structure of the
antibody. The Baba antibody is a pentameric IgM immunoglobulin
that contains 10 binding sites capable of multivalent interactions
with carbohydrate ligands. van de Weerd et al. (2015) suggested
that high affinity binding requires the antibody to interact with mul-
tiple α-1,4-linked linear maltotriose epitopes, potentially straddling
multiple polyglucose chains. Therefore, more densely branched glu-
cose polymers like glycogen may provide more effective epitopes for
each molecule of the multivalent antibody when compared with less
branched polymers. In contrast, the smaller GYSC is able to bind
glucose polymers such as amylose that are almost devoid of
branches, possibly indicating that the binding “epitope” is a short
segment of polyglucose. However, when used to detect glycogen in
cultured cells, both the Baba antibody and GYSC gave similar and
consistent results, with strong co-localization of the respective sig-
nals. As a more stringent test, we assessed the ability of GYSC to
visualize glycogen deposits in muscle fibers from two animal models
of GSDs, Pompe disease and Lafora disease.
We were able to demonstrate co-localization of glycogen and
lysosomes in muscle fibers from Pompe mice (Figure 7), to our
knowledge the first visualization of glycogen within the lysosome by
immunofluorescent staining. Interestingly, this was the one instance
Fig. 6. Detection of Lafora bodies in single psoas fiber from Epm2b–/– mice. The immunofluorescence analysis was performed with anti-glycogen antibodies (A)
and GYSC (B). The images were merged (C). Nuclei were stained with Hoechst. This figure is available in black and white in print and in color at Glycobiology
online.
Fig. 7. Localization of glycogen within lysosomes in single anterior tibialis
fiber from GAA–/– mice. Confocal image of single muscle fiber stained with
GYSC and antibody against lysosomal membrane protein Lamp1. The
images were merged. Nuclei were stained with Hoechst. A representative
Z-stack image is shown. This figure is available in black and white in print
and in color at Glycobiology online.
420 AV Skurat et al.
where the behaviors of GYSC and the Baba antibody differed, the
anti-glycogen antibody failing to detect glycogen inside the lyso-
somes. Possibly, the lysosomal membrane is not permeable to the anti-
glycogen antibody under the conditions used for preparation of muscle
fibers. The large size of the IgM molecule (970 kDa) may make it be
too large to cross the lysosomal membrane whereas GYSC is much
smaller, with molecular mass of a monomer ~39 kDa (Figure 1B).
GYSC also detected glycogen deposits in muscle fibers from a
mouse model of Lafora disease, Epm2b–/– mice (Figure 6). In this
case, both GYSC and the Baba antibody gave signals that were essen-
tially coincident. One could expect that the anti-glycogen antibody
would be ineffective in recognizing the glycogen in the Epm2b–/– mice
since it is poorly branched, especially in Lafora bodies. However, it is
only a subset of the Lafora glycogen that is abnormal and in addition,
the aggregates of glycogen molecules that become insoluble will likely
carry along normally branched glycogen.
In conclusion, we have developed and validated a novel probe
for glycogen that may have utility for the study of glycogen in cells
and which may help advance understanding of the abnormal glyco-
gen metabolism associated with GSDs.
Materials and methods
Antibodies
Rabbit anti-GST antibody and mouse monoclonal anti-glycogen
antibody IV58B6 were kindly provided by Dr Clark Wells (Indiana
University School of Medicine, Indianapolis, IN) and Dr O. Baba
(Tokyo Medical and Dental University, Tokyo, Japan), respectively.
Other primary antibodies include anti-glycogen synthase (AHO1412,
Invitrogen, Camarillo, CA and NB110-57010, Novus Biologicals,
Littleton, CO), anti-Myc (9E10, Santa Cruz Biotechnology, Santa
Cruz, CA) and anti-Lamp1 (1D4B, Developmental Studies
Hybridoma Bank, Iowa City, IA).
Plasmid construction and protein purification
To generate pGEX-myc-Stbd1CBM, a DNA fragment encoding resi-
dues 261–358 of human Stbd1 was amplified by PCR using Stbd1
cDNA as template and two primers, one of which additionally con-
tained sequence encoding a cMyc epitope tag (EQKLISEEDL). The
resulting DNA fragment was subcloned into pGEX-4T1 to generate a
vector that would encode a fusion protein containing GST–cMyc–
Stbd1CBM, which we named GYSC. The plasmid was used to trans-
form E. coli cell BL21/DE3. Transformants were isolated, induced
with IPTG and the recombinant protein, GYSC, was purified over
glutathione agarose. Bound GYSC was eluted with glutathione elution
buffer (50mM Tris–HCl, 10mM reduced glutathione, pH 8.0), frac-
tions were collected and analyzed by SDS-PAGE followed by
Coomassie blue staining. Fractions with highest concentration of
GYSC were pooled, frozen in liquid nitrogen and stored at −80°C.
Enzyme-linked immunosorbent assay
Rabbit liver glycogen (G-8876, Sigma-Aldrich, St Louis, MO) and
potato amylopectin (A8515, Sigma-Aldrich) were dissolved in
phosphate-buffered saline (PBS) to the final concentration of 1 mg/
mL. Corn amylose (A-7043, Sigma-Aldrich) was dissolved in 1M
NaOH at 50mg/mL and then diluted in PBS to a final concentration
of 0.1mg/mL. Serial dilutions of the polysaccharides in PBS were
prepared and used to coat the wells of microtiter plates (3590,
Costar, Cambridge, MA) for 2 h at 37°C. After coating, blocking
buffer (BB), PBS containing 5% bovine serum albumin (BSA) and
0.1% Triton X-100 was added, and the plate was incubated for 2 h
at room temperature. For determination of GYSC binding to poly-
saccharides, purified GYSC was diluted in BB to a final concentra-
tion of 0.55 μg/mL, added to the wells and incubated for 16 h at 4°
C. To detect bound GYSC, rabbit anti-GST antibody diluted 1:1000
was added to the wells and incubated for 2 h at room temperature
followed by incubation with horseradish peroxidase (HRP)-conju-
gated goat anti-rabbit IgG antibody (31460, Thermo Fisher
Scientific, Rockford, IL) diluted 1:30,000. The bound antibody was
detected by adding 0.1mL TMB reagent (Ultra TMB-ELISA,
Thermo Fisher Scientific) followed by termination of the reaction by
0.1mL 2M H2SO4 and measurement of absorbance at 450 nm.
Between each step, the wells were washed three times with buffer
consisting of PBS and 0.1% Triton X-100.
Binding of anti-glycogen antibody to polysaccharides was mea-
sured by a similar procedure. After blocking, mouse anti-glycogen
antibody was added to the wells and incubated for 16 h at 4°C. As a
secondary antibody, HRP-labeled goat anti-mouse IgG+IgM anti-
body (31444, Thermo Fisher Scientific) was used.
Cell culture, glucose starvation and refeeding
Rat-1 fibroblasts were grown on chamber slides (80826, Ibidi,
Madison, WI) in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS). Cell starvation was
performed by incubation of Rat-1 fibroblasts for 48 h in glucose-free
DMEM, supplemented with 10% FBS and 1mM sodium pyruvate.
For refeeding, cell starvation medium was removed and DMEM con-
taining 25mM glucose, 10% FBS and 1mM sodium pyruvate was
added, and cells were incubated for 6 h. Generation of the Rat-1 fibro-
blast clone stably expressing wild type rabbit muscle glycogen synthase
(clone WT-4) was described previously (Skurat et al. 2000). WT-4 cells
were grown in DMEM, supplemented with 10% FBS and 0.25mg/mL
G418 (10131035, Thermo Fisher Scientific). All media additionally con-
tained 100U/mL penicillin and 0.1mg/mL streptomycin.
Immunofluorescence analysis of glycogen in Rat-1 cells
Cells were fixed and permeabilized with methanol for 6min at −20°C
and then slides were incubated with blocking solution (5% BSA and
0.1% Triton X-100 in PBS) overnight at 4°C. In experiments with
GYSC, the polypeptide was diluted in blocking solution to a final
concentration of 0.28 μg/mL, added to fixed cells and incubated for
2 h at 22°C. After washing three times with PBS buffer containing
0.1% Triton X-100, the slides were exposed to a primary antibody
against GST (dilution 1:200) and against other proteins of interest
or glycogen in blocking solution for 2 h at room temperature.
Antibodies against glycogen, glycogen synthase and c-Myc were
used in dilutions 1:100, 1:200 and 1:500, respectively. The bound
antibodies were visualized using secondary antibodies conjugated
with Alexa Fluor or Texas Red (Invitrogen, Eugene, OR) diluted
1:1000. Nuclei were stained with 1 μg/mL Hoechst 33258 dye. Cells
were mounted with ProLong Gold (P36930, Invitrogen) and immu-
nostaining was visualized under fluorescence microscopy. All epifluor-
escence imaging was acquired on Zeiss Axio Observer Z1 microscope
with a c-apochromat_40 water immersion objective (Zeiss, Jena,
Germany). Images were processed with Zeiss Axiovision 4.7.
Amyloglucosidase and diastase treatment
After fixation and permeabilization with methanol, cells were incu-
bated with 0.4mg/mL amyloglucosidase (A7420, Sigma-Aldrich) or
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0.5% diastase of malt (D22-100, Fisher Scientific, Fair Lawn, NJ)
dissolved in PBS containing 5% BSA for 18 h at room temperature.
Cells were then processed for incubation with GYSC and appropri-
ate antibodies.
Glycogen determination
Glycogen content in the Rat-1 fibroblasts was measured by modifi-
cations of Suzuki et al. (2001). Rat-1 fibroblasts were seeded in
60-mm plates and grown till 100% confluence. After glucose starva-
tion and refeeding, cell extracts were prepared as described previ-
ously (Skurat et al. 1993). Briefly, cells were rinsed twice with 4mL
homogenization buffer (50mM Tris–HCI pH 7.8, 10 mM EDTA,
2mM EGTA, 100mM NaF). Cells were then frozen in liquid nitro-
gen in 0.3mL homogenization buffer. After thawing, lysed cells
were collected by scraping with a rubber policeman and homoge-
nized with a tissue tearer. Homogenates were centrifuged at 6000 ×
g for 10min. Glycogen standard solutions and samples of super-
natant were hydrolyzed in 30% (w/v) KOH solution in a boiling
water bath. After precipitation with ethanol, glycogen was hydro-
lyzed by amylo-1,6-glycosidase at pH 4.8, and the resulting glucose
was determined by the hexokinase/glucose-6-phosphate dehydrogen-
ase reaction (Suzuki et al. 2001). Glycogen content was expressed as
micrograms of glycogen per milligram of protein. Protein concentra-
tion was determined by the Bradford method using BSA as standard
(Bradford 1976).
Isolation of fixed single muscle fibers from mouse
models of glycogenoses and immunofluorescence
microscopy
Two mouse models of glycogenoses were analyzed. The first, GAA–/–
mice, which lack lysosomal α-glucosidase (acid maltase) activity,
were kindly supplied by Dr. Nina Raben. These mice over-
accumulate glycogen in lysosomes and other vesicular stores and
have been studied as a model for Pompe disease (Raben et al. 1998,
2003). The second, Epm2b–/– mice were generated in our laboratory
(DePaoli-Roach et al. 2010) and lack the malin protein (Chan et al.
2003). Mutations of either EPM2B or a second gene, EPM2A,
which encodes the glycogen phosphatase called laforin (Minassian
et al. 1998), cause Lafora disease in humans (Ganesh et al. 2006;
Ramachandran et al. 2009). Lafora disease, which is a teenage onset
progressive myoclonus epilepsy, appears to result from the over-
accumulation of abnormally insoluble deposits of glycogen (Collins
et al. 1968; Carpenter and Karpati 1981; DiMauro and Lamperti
2001). Muscle fibers were isolated from mice as described previously
(Raben et al. 2009). Briefly, psoas and anterior tibialis muscle sam-
ples were removed immediately after sacrifice from Epm2b–/– mice
(351 days old) and GAA–/– mice (324 days old), respectively.
Muscles were pinned to a Sylgard-coated dish and submerged in 4%
paraformaldehyde in PBS for 30min for fixation at room tempera-
ture. Samples were then transferred to cold methanol, and placed at
−20°C for 6min. After washing with PBS, samples were placed in
50% glycerol in PBS and stored at −20°C. Single fibers obtained by
manual teasing were incubated for 1 h in a blocking solution con-
sisting of PBS, 0.08% Saponin and blocking reagent from Vector M.
O.M. Immunodetection Kit (Vector Laboratories, Burlingame, CA).
After blocking, fibers were placed in diluent solution containing
PBS, protein concentrate (M.O.M. kit) and 0.08% Saponin followed
by addition of GYSC to a final concentration 1.1 μg/mL. Fibers were
incubated for 16 h at 4°C, washed in PBS containing 0.08%
Saponin and incubated with primary antibodies against GST and
Lamp1 or glycogen for 2 h at room temperature. Fibers were
washed again, incubated with secondary antibody for 1 h at room
temperature and mounted in Vectashield (Vector Laboratories,
Burlingame, CA) on a glass slide for analysis by immunofluorescent
microscopy. For each immunostaining, at least 20 fibers were iso-
lated from psoas or anterior tibialis muscle. Images of muscle fibers
from GAA–/– mice were acquired with a confocal/2-photon Leica
TCS SP8 system (Leica Microsystems, Inc., Buffalo Grove, IL) by
using Leica HC PL APO 40×/1.3 oil immersion objective. Series of
sections through the depth of tissue (Z-stacks) were collected by
using optimal step size settings (0.35 μm); images were composed of
512 × 512 pixels (92.3 × 92.3 μm2).
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